Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Lasa Supergenerics Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 2:15 am

Market Cap 144 Cr.
Current Price 28.8
High / Low 41.2/19.0
Stock P/E
Book Value 18.1
Dividend Yield0.00 %
ROCE6.45 %
ROE13.2 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lasa Supergenerics Ltd

Competitors of

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
HP Adhesives Ltd 725 Cr. 78.9 131/75.035.2 19.20.38 %17.7 %12.6 % 2.00
Haryana Leather Chemicals Ltd 44.4 Cr. 90.5 124/56.89.83 87.21.10 %8.96 %7.25 % 10.0
Hardcastle & Waud Mfg Co Ltd 61.8 Cr. 909 1,355/45132.4 6630.00 %7.00 %5.98 % 10.0
Grauer & Weil (India) Ltd 4,577 Cr. 101 120/63.528.6 19.20.50 %26.1 %19.6 % 1.00
DMCC Speciality Chemicals Ltd 972 Cr. 390 453/24573.3 85.40.26 %10.8 %5.68 % 10.0
Industry Average12,868.59 Cr928.7458.01173.840.31%14.09%10.82%6.44

All Competitor Stocks of

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales53.9939.1036.0734.1115.7451.2128.8833.6631.7035.3230.5624.3026.66
Expenses41.2430.0131.4432.8616.9240.4637.0133.9934.1630.9826.5123.2525.60
Operating Profit12.759.094.631.25-1.1810.75-8.13-0.33-2.464.344.051.051.06
OPM %23.62%23.25%12.84%3.66%-7.50%20.99%-28.15%-0.98%-7.76%12.29%13.25%4.32%3.98%
Other Income0.02-0.000.01-11.880.014.240.01-2.470.86-18.97-0.000.08-0.00
Interest0.080.030.03-0.000.010.010.010.840.430.410.370.560.44
Depreciation4.093.943.473.453.593.613.073.093.094.172.652.682.68
Profit before tax8.605.121.14-14.08-4.7711.37-11.20-6.73-5.12-19.211.03-2.11-2.06
Tax %23.84%25.78%29.82%2.41%1.05%-6.68%-7.95%2.08%3.91%21.92%580.58%99.05%29.61%
Net Profit6.563.800.81-13.74-4.7112.13-12.08-6.61-4.92-15.00-4.95-0.02-1.46
EPS in Rs1.610.930.20-3.38-1.162.98-2.97-1.63-1.21-2.99-0.99-0.00-0.29

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales0199244170167201137130122
Expenses0153202158137154120136115
Operating Profit0464111304716-67
OPM %23%17%7%18%24%12%-5%6%
Other Income0-243000-8-18-18
Interest01211882042
Depreciation0818191716151313
Profit before tax0215-16530-6-42-25
Tax %-10%19%25%23%23%13%9%
Net Profit0212-12423-5-39-26
EPS in Rs5.40-5.260.895.60-1.31-7.71-5.46
Dividend Payout %0%0%0%0%4%-24%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)500.00%-200.00%133.33%475.00%-121.74%-680.00%
Change in YoY Net Profit Growth (%)0.00%-700.00%333.33%341.67%-596.74%-558.26%

Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2017-2018 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:%
5 Years:-9%
3 Years:-20%
TTM:-2%
Compounded Profit Growth
10 Years:%
5 Years:-4%
3 Years:%
TTM:-180%
Stock Price CAGR
10 Years:%
5 Years:10%
3 Years:-26%
1 Year:4%
Return on Equity
10 Years:%
5 Years:-1%
3 Years:-8%
Last Year:-13%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:15 pm

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital0.050.052323414150505050
Reserves0759482101118108684741
Borrowings011610785481920222220
Other Liabilities0376369422931243236
Total Liabilities0228287258232208209164151147
Fixed Assets0119170162152143137119110105
CWIP03077005533
Investments0000000000
Other Assets08011090806567403940
Total Assets0228287258232208209164151147

Reserves and Borrowings Chart

Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +0-3404114419-172
Cash from Investing Activity +00-44-7-2-4-311-0
Cash from Financing Activity +004-33-10-36-0-4-2
Net Cash Flow0-30-0216-10-0

Free Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow0.00-70.00-66.00-74.00-18.0028.00-4.00-28.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days646362452750713
Inventory Days93909010156464892
Days Payable7110217013041683268
Cash Conversion Cycle8751-181642282237
Working Capital Days5844-2313512-1734
ROCE %42%13%-4%7%17%1%-12%-6%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters45.01%43.78%43.78%43.78%43.78%53.65%53.65%53.65%53.65%53.65%53.65%53.65%
FIIs0.06%0.00%0.40%0.00%0.00%0.00%0.00%0.00%0.01%0.12%0.00%0.01%
Public54.93%56.21%55.82%56.21%56.21%46.34%46.34%46.34%46.33%46.23%46.34%46.32%
No. of Shareholders24,82727,85930,08729,69228,93628,81828,03127,77027,16127,61527,21727,968

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-4.34-7.71-1.305.601.26
Diluted EPS (Rs.)-4.34-7.71-1.305.601.26
Cash EPS (Rs.)-2.21-5.032.129.495.16
Book Value[Excl.RevalReserv]/Share (Rs.)19.3023.6136.5439.0734.78
Book Value[Incl.RevalReserv]/Share (Rs.)19.3023.6136.5439.0734.78
Dividend / Share (Rs.)0.000.000.250.250.00
Revenue From Operations / Share (Rs.)20.8225.8633.7149.7641.13
PBDIT / Share (Rs.)0.45-0.953.8611.627.42
PBIT / Share (Rs.)-1.68-3.630.417.733.16
PBT / Share (Rs.)-3.81-8.44-1.537.251.16
Net Profit / Share (Rs.)-4.34-7.71-1.325.600.89
PBDIT Margin (%)2.17-3.6911.4423.3618.04
PBIT Margin (%)-8.05-14.051.2315.547.67
PBT Margin (%)-18.31-32.62-4.5214.572.83
Net Profit Margin (%)-20.82-29.80-3.9111.252.16
Return on Networth / Equity (%)-22.47-32.65-3.6114.332.56
Return on Capital Employeed (%)-8.24-15.031.0818.798.22
Return On Assets (%)-14.40-23.57-2.6910.951.56
Long Term Debt / Equity (X)0.000.000.000.000.09
Total Debt / Equity (X)0.000.000.000.000.24
Asset Turnover Ratio (%)0.660.710.670.920.68
Current Ratio (X)0.770.911.651.590.99
Quick Ratio (X)0.380.591.391.160.65
Inventory Turnover Ratio (X)4.818.676.134.692.99
Interest Coverage Ratio (X)1.17-1.15389.3324.083.72
Interest Coverage Ratio (Post Tax) (X)-5.71-3.5062.8612.601.45
Enterprise Value (Cr.)108.5890.15152.41239.23143.93
EV / Net Operating Revenue (X)1.040.691.111.180.86
EV / EBITDA (X)47.93-18.829.715.064.77
MarketCap / Net Operating Revenue (X)1.050.711.241.200.69
Price / BV (X)1.140.781.141.530.81
Price / Net Operating Revenue (X)1.050.711.241.200.69
EarningsYield-0.19-0.41-0.030.090.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lasa Supergenerics Ltd as of December 22, 2024 is: 36.55

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, Lasa Supergenerics Ltd is Undervalued by 26.91% compared to the current share price 28.80

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Lasa Supergenerics Ltd as of December 22, 2024 is: 24.53

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, Lasa Supergenerics Ltd is Overvalued by 14.83% compared to the current share price 28.80

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -32.90%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of 21.67, which is a positive sign.
  2. The company has higher reserves (73.40 cr) compared to borrowings (45.90 cr), indicating strong financial stability.
  1. The stock has a low average ROCE of 6.44%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 29.44, which may not be favorable.
  3. The company has not shown consistent growth in sales (152.22) and profit (-4.11).

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
    1. Net Profit Margin: -20.82%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -8.24% (Industry Average ROCE: 14.09%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -22.47% (Industry Average ROE: 10.82%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -5.71
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.38
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 58.01)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Lasa Supergenerics Ltd. is a Public Limited Listed company incorporated on 11/11/2016 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24233MH2016PLC274202 and registration number is 274202. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company’s Total Operating Revenue is Rs. 137.13 Cr. and Equity Capital is Rs. 40.67 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Chemicals - Speciality - OthersPlot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722investor@lasalabs.com
http://www.lasalabs.com
Management
NamePosition Held
Dr. Omkar Pravin HerlekarChairman & Managing Director
Mr. Umesh S PawarExecutive Director
Mr. Ajay SukhwaniIndependent Director
Ms. Manali BhagtaniIndependent Director
Ms. Ekta GurnasinghaniIndependent Director
Mr. Hardesh TolaniIndependent Director

FAQ

What is the latest intrinsic value of Lasa Supergenerics Ltd?

The latest intrinsic value of Lasa Supergenerics Ltd as on 22 December 2024 is ₹36.55, which is 26.91% higher than the current market price of ₹28.80. The stock has a market capitalization of 144 Cr. and recorded a high/low of 41.2/19.0 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹41 Cr and total liabilities of ₹147 Cr.

What is the Market Cap of Lasa Supergenerics Ltd?

The Market Cap of Lasa Supergenerics Ltd is 144 Cr..

What is the current Stock Price of Lasa Supergenerics Ltd as on 22 December 2024?

The current stock price of Lasa Supergenerics Ltd as on 22 December 2024 is 28.8.

What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Lasa Supergenerics Ltd stocks is 41.2/19.0.

What is the Stock P/E of Lasa Supergenerics Ltd?

The Stock P/E of Lasa Supergenerics Ltd is .

What is the Book Value of Lasa Supergenerics Ltd?

The Book Value of Lasa Supergenerics Ltd is 18.1.

What is the Dividend Yield of Lasa Supergenerics Ltd?

The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.

What is the ROCE of Lasa Supergenerics Ltd?

The ROCE of Lasa Supergenerics Ltd is 6.45 %.

What is the ROE of Lasa Supergenerics Ltd?

The ROE of Lasa Supergenerics Ltd is 13.2 %.

What is the Face Value of Lasa Supergenerics Ltd?

The Face Value of Lasa Supergenerics Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lasa Supergenerics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE